WO2011133870A3 - Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap) - Google Patents

Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap) Download PDF

Info

Publication number
WO2011133870A3
WO2011133870A3 PCT/US2011/033591 US2011033591W WO2011133870A3 WO 2011133870 A3 WO2011133870 A3 WO 2011133870A3 US 2011033591 W US2011033591 W US 2011033591W WO 2011133870 A3 WO2011133870 A3 WO 2011133870A3
Authority
WO
WIPO (PCT)
Prior art keywords
sap
adenovirus vectors
vaccines
polypeptide
interest
Prior art date
Application number
PCT/US2011/033591
Other languages
French (fr)
Other versions
WO2011133870A2 (en
Inventor
Andrea Amalfitano
Yasser Aldhamen
Seregin Sergey
Original Assignee
Andrea Amalfitano
Yasser Aldhamen
Seregin Sergey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrea Amalfitano, Yasser Aldhamen, Seregin Sergey filed Critical Andrea Amalfitano
Publication of WO2011133870A2 publication Critical patent/WO2011133870A2/en
Publication of WO2011133870A3 publication Critical patent/WO2011133870A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides replication incompetent adenovirus vectors containing a heterologous nucleic acid sequence that encodes at least a portion of a SLAM family receptor adaptor protein (SAP), and optionally further encodes a polypeptide of interest. The compositions and methods are useful for enhancing a subject's immune response to a polypeptide of interest by expression, in one or more vectors, of the polypeptide of interest and a SLAM family receptor adaptor protein. Furthermore, the compositions and methods are also useful for induction of an innate immune response and/or an adaptive cellular and/or humoral immune response for vaccination applications.
PCT/US2011/033591 2010-04-22 2011-04-22 Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap) WO2011133870A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32688010P 2010-04-22 2010-04-22
US61/326,880 2010-04-22

Publications (2)

Publication Number Publication Date
WO2011133870A2 WO2011133870A2 (en) 2011-10-27
WO2011133870A3 true WO2011133870A3 (en) 2011-12-22

Family

ID=44834828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033591 WO2011133870A2 (en) 2010-04-22 2011-04-22 Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)

Country Status (1)

Country Link
WO (1) WO2011133870A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130787B2 (en) 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086837A1 (en) * 2000-12-21 2002-07-04 Jack Gauldie Acne vaccine
US20040241181A1 (en) * 2001-06-22 2004-12-02 Ertl Hildeghund C. J. Methods of inducing a cytotoxic immune response and recormbinant simian adenovirus compositions useful therein
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
US20100015654A1 (en) * 2005-05-16 2010-01-21 Institut De Recherches Cliniques De Montreal/ I.R.C.M. Negative regulation of NK cell functions by EAT-2, a sap-related adaptor expressed in innate immune cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086837A1 (en) * 2000-12-21 2002-07-04 Jack Gauldie Acne vaccine
US20040241181A1 (en) * 2001-06-22 2004-12-02 Ertl Hildeghund C. J. Methods of inducing a cytotoxic immune response and recormbinant simian adenovirus compositions useful therein
US20100015654A1 (en) * 2005-05-16 2010-01-21 Institut De Recherches Cliniques De Montreal/ I.R.C.M. Negative regulation of NK cell functions by EAT-2, a sap-related adaptor expressed in innate immune cells
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALDHAMEN ET AL.: "Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens.", J IMMUNOL., vol. 186, no. 2, 13 December 2010 (2010-12-13), pages 722 - 732 *
CALPE ET AL.: "The SLAM and SAP gene families control innate and adaptive immune responses.", ADV IMMUNOL, vol. 97, 2008, pages 177 - 250 *
CANNONS ET AL.: "SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation.", J EXP MED, vol. 203, no. 6, 5 June 2006 (2006-06-05), pages 1551 - 1565 *
DATABASE GENBANK [online] 4 November 2001 (2001-11-04), BOUCHON, A. ET AL.: "Homo sapiens EWS/FLI1 activated transcript 2 protein mRNA, complete cds.", retrieved from http:// http://www.ncbi.nlm.nih.gov/nuccore/AF403479 Database accession no. AF403479 *
DUPRE, L. ET AL.: "SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells.", BLOOD., vol. 105, no. 11, 27 January 2005 (2005-01-27), pages 4383 - 4389 *
VEILLETTE, A.: "Immune regulation by SLAM family receptors and SAP-related adaptors.", NAT REV IMMUNOL., vol. 6, January 2006 (2006-01-01), pages 56 - 66 *

Also Published As

Publication number Publication date
WO2011133870A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
MX2014009845A (en) Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom.
MX2009012812A (en) Mutated parvovirus structural proteins as vaccines.
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2009079564A3 (en) Immunogenic compositions and methods of use thereof
WO2010149752A3 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
WO2007087178A3 (en) Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
EP3156070A3 (en) Newcastle disease virus vectored herpesvirus vaccines
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
WO2010105251A3 (en) Non-integrating retroviral vector vaccines
WO2009117116A3 (en) Heat shock protein gp96 vaccination and methods of using same
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
AU2012342117A8 (en) Recombinant proteins and their therapeutic uses
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
MX2018013081A (en) Methods for predicting the usefulness of proteins or protein fragments for immunotherapy.
MX2009007572A (en) Fusion protein.
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
WO2012115715A3 (en) Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
MX354752B (en) Heterologous prime boost vaccination regimen against malaria.
WO2011133870A3 (en) Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)
MX351642B (en) Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772769

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11772769

Country of ref document: EP

Kind code of ref document: A2